Clinical characteristics and outcomes of oropharyngeal carcinoma related to high‐risk non–human papillomavirus16 viral subtypes

Varier, Indu; Keeley, Brieze R.; Krupar, Rosemarie; Patsias, Alexis; Dong, Joanna; Gupta, Nikita; Parasher, Arjun K.; Genden, Eric M.; Miles, Brett A.; Teng, Marita S.; Bakst, Richard L.; Gupta, Vishal; Misiukiewicz, Krzysztof; Chiao, Elizabeth Y.; Scheurer, Michael E.; Laban, Simon; Zhang, David; Ye, Fei; Cui, Miao; Demicco, Elizabeth G.; Posner, Marshall R.; Sikora, Andrew G.

doi:10.1002/hed.24442

Cited by 34 publications

(31 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Differences in the sensitivity of these detection methods may have led to misclassification and explain the different prognostic effects observed in our study compared to previous studies. However, our findings are consistent with a recent study that also used single‐center tumor testing and a diversely sampled population . It concluded that there were no differences in survival between HPV16 and other non‐HPV16 types in OPSCCs …”

Section: Discussionsupporting

confidence: 92%

Prognostic factors for human papillomavirus–positive and negative oropharyngeal carcinomas

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

Prognostic factors for human papillomavirus–positive and negative oropharyngeal carcinomas

et al. 2018

View full text Add to dashboard Cite

show abstract

“…However, few studies have examined survival trends in cases stratified by HPV genotype [7–9]. Bratman et al demonstrated a significant survival benefit for HPV16-positive cases (N = 61) compared with non-HPV16-positive (N = 12) and HPV-negative (N = 442) among all HNSCC (log-rank: <0.001) with cases from The Cancer Genome Atlas [7].…”

Section: Discussionmentioning

confidence: 99%

“…Two other groups in the United States conducted studies comparing HPV genotypes in OPSCC. A study by Varier et al found HPV16-positive OPSCC from the Icahn School of Medicine at Mount Sinai had non-significantly better survival than patients with non-HPV16-positive OPSCC (n=27) [9]. Another study from Centers for Disease Control Cancer Registry Sentinel Surveillance, a cancer registry-based residual tissue, also found decreased survival for cases with non-HPV16-positive OPSCC compared to HPV16-positive OPSCC even after adjustment for covariates [6].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic significance of non-HPV16 genotypes in oropharyngeal squamous cell carcinoma

et al. 2016

View full text Add to dashboard Cite

Objectives Recent studies have found that cases with oropharyngeal squamous cell carcinoma (OPSCC) positive for HPV16 genotype have better overall survival compared with cases positive for other HPV genotypes. We sought to further replicate these studies and determine if this relationship is modified by expression of p16 tumor suppressor protein. Material and Methods We identified 238 OPSCC cases from the Carolina Head and Neck Cancer Study (CHANCE) study, a population based case-control study. Tumors that tested positive solely for HPV16 genotype and no other genotypes with PCR were classified as HPV16-positive. Tumors positive for any other high-risk HPV genotype were classified as non-HPV16-positive. Expression of p16 in the tumor was determined with immunohistochemistry. Follow-up time was calculated from the date of diagnosis to date of death or December 31, 2013. Overall survival was compared with the Kaplan-Meier curves and log-rank test. Hazard ratios (HR) adjusted for smoking, alcohol use, sex, race, and age was calculated with the Cox proportional hazard regression. Results Cases with HPV16-positive OPSCC had better overall survival than cases with non-HPV16-positive OPSCC (log-rank p-value: 0.010). When restricted to OPSCC cases positive for p16 expression, the same trend continued (log-rank p-value: 0.002). In the adjusted model, cases with non-HPV16-positive OPSCC had greater risk of death compared to cases with HPV16-positive tumors (HR: 1.92; 95% CI: 1.03, 3.60). Conclusions This finding indicates that HPV genotyping carries valuable prognostic significance in addition to p16 status and future survival studies of OPSCC should take into account differing HPV genotypes.

show abstract

“…In the United States it has recently been approximated that HPV-related head and neck cancers incidence is likely to surpass that of cervical cancers by the year 2020 [32]. The primary viral etiology of these cancers is HPV-16; however, up to 9% may be caused by additional serotypes (e.g., HPV-35, HPV-18) [33]. Despite increasing awareness and improved viral detection methods, identification of active disease remains problematic [34].…”

Section: Hpv-associated Cancers and Current Therapiesmentioning

confidence: 99%

Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11–001

Miles

Safran

Monk

2017

gynaecol oncol res pract

View full text Add to dashboard Cite

Survival of patients with advanced, recurrent, or metastatic human papillomavirus (HPV)-associated cancer is suboptimal despite the availability of various treatment modalities. The recently developed bacterial vector Listeria monocytogenes (Lm) activates innate and adaptive immune responses and is expected to offer immunologic advantages. Axalimogene filolisbac (AXAL or ADXS11–001) is a novel immunotherapeutic based on the live, irreversibly attenuated Lm fused to the nonhemolytic fragment of listeriolysin O (Lm-LLO) and secretes the Lm-LLO-HPV E7 fusion protein targeting HPV-positive tumors. Herein are reported the development and recent results of various clinical trials in patients with HPV-associated cervical, head and neck, and anal cancers.

show abstract

Clinical characteristics and outcomes of oropharyngeal carcinoma related to high‐risk non–human papillomavirus16 viral subtypes

Cited by 34 publications

References 29 publications

Prognostic factors for human papillomavirus–positive and negative oropharyngeal carcinomas

Prognostic factors for human papillomavirus–positive and negative oropharyngeal carcinomas

Prognostic significance of non-HPV16 genotypes in oropharyngeal squamous cell carcinoma

Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11–001

Contact Info

Product

Resources

About